Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models.
Ann Clin Transl Neurol
; 2(10): 978-83, 2015 Oct.
Article
em En
| MEDLINE
| ID: mdl-26478898
ABSTRACT
Dimethyl fumarate is an orally bioavailable compound for the treatment of multiple sclerosis and psoriasis. A mechanism involving nuclear factor erythroid 2-like 2 activation has been proposed to account for its efficacy in multiple sclerosis. Here, we report that dimethyl fumarate inhibits expression of integrin α4 on circulating lymphocytes in experimental autoimmune encephalomyelitis mice and also on activated human Jurkat T cells in a manner distinct from nuclear factor erythroid 2-like 2 activation. Our results offer an alternative mechanism for the efficacy of dimethyl fumarate in multiple sclerosis.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
Idioma:
En
Revista:
Ann Clin Transl Neurol
Ano de publicação:
2015
Tipo de documento:
Article